Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review

Autor: Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen

Publikováno v: Brinch, C M, Aggerholm-Pedersen, N, Hogdall, E & Krarup-Hansen, A 2022, ' Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review ', Critical Reviews in Oncology/Hematology, vol. 172, 103650 . https://doi.org/10.1016/j.critrevonc.2022.103650
Brinch, C M, Aggerholm-Pedersen, N, Hogdall, E & Krarup-Hansen, A 2022, ' Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST)-a Systematic Review ', Critical Reviews in Oncology/Hematology, vol. 172, 103650 . https://doi.org/10.1016/j.critrevonc.2022.103650

BACKGROUND: Chemotherapy is ineffective in treating patients with Gastrointestinal Stromal Tumour (GIST). However, several types of tyrosine kinase inhibitors have been investigated since the approval of imatinib in 2001. The purpose of this report w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5db02a1b6c408fcf19841b268cd8ced
https://curis.ku.dk/portal/da/publications/medical-oncological-treatment-for-patients-with-gastrointestinal-stromal-tumor-gist--a-systematic-review(874c2118-ad24-4c15-b244-b929b079342f).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

Autor: Angelo Paolo Dei Tos, Rossella Bertulli, Alberto Pisacane, Dario Sangiolo, Stefano Ferrari, Massimo Aglietta, Francesco Tolomeo, Lorenzo D'Ambrosio, Luca Novara, Sandra Aliberti, R. Piana, Giovanni Grignani, Emanuela Marchesi, Giulia Chiabotto, Maurizio D'Incalci, Paola Boccone, Alice Bartolini, Alberto Bardelli, Emanuela Palmerini, Sara Miano, Silvia Stacchiotti, Massimo Zucchetti, Piero Picci, Ymera Pignochino

Summary Background Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78da60dd3ec41f959b0a92e8b7dc0224
http://hdl.handle.net/2318/1678537

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.